Bumper Offer - Urjas oil Just @ Rs. 1
Minirin Melt 0.1 Tablet is a commercial drug that is prescribed in the form of Tablet. It is primarily used for the treatment of Bedwetting, Diabetes Insipidus. Secondary and off-label uses of Minirin Melt 0.1 Tablet have also been mentioned below.
The right dosage of Minirin Melt 0.1 Tablet depends on the age, gender, and medical history of the patient. The condition it has been prescribed for, and the route of administration also determine the right dosage. This information has been provided in detail in the dosage section.
Apart from the aforementioned side effects, Minirin Melt 0.1 Tablet can also lead to other problems, which have been listed below. Such side effects of Minirin Melt 0.1 Tablet normally do not last long and go away once the treatment is completed. However, if these continue for a longer time, consult your doctor right away.
Minirin Melt 0.1 Tablet's effect during pregnancy is Unknown and Unknown while nursing. Warnings related to Minirin Melt 0.1 Tablet's effects on the liver, heart and kidney, if any, have been listed below.
Other contraindications of Minirin Melt 0.1 Tablet have been discussed in the sections ahead.
Drug interactions for Minirin Melt 0.1 Tablet have been reported in the medical literature. A complete list of these interactions is given below.
In addition to the above precautions for Minirin Melt 0.1 Tablet, it is important to know that it is safe while driving, and is habit-forming.
Minirin Melt 0.1 Tablet is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| Geriatric |
|
| 13 - 18 years (Adolescent) |
|
Based on research, the following side effects have been observed when Minirin Melt 0.1 Tablet is used -
Moderate
Mild
Is the use of Minirin Melt 0.1 Tablet safe for pregnant women?
Side effects of Minirin during pregnancy are not known because scientific research on this topic hasn't been done.
Is the use of Minirin Melt 0.1 Tablet safe during breastfeeding?
Information about safety of Minirin for women who are breastfeeding is not available since scientific research on this is yet to be done.
What is the effect of Minirin Melt 0.1 Tablet on the Kidneys?
Using Minirin does not have any harmful effects on kidneys.
What is the effect of Minirin Melt 0.1 Tablet on the Liver?
Very few cases of side effects of Minirin on the liver have been reported.
What is the effect of Minirin Melt 0.1 Tablet on the Heart?
You may experience side effects on your heart after taking Minirin. If this happens, then discontinue its use. Consult your medical practitioner, and do as he/she suggests.
Minirin Melt 0.1 Tablet should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Minirin Melt 0.1 Tablet unless your doctor advises you to do so -
Is this Minirin Melt 0.1 Tablet habit forming or addictive?
Minirin Melt 0.1 Tablet is not addictive in nature.
Is it safe to drive or operate heavy machinery when consuming?
Yes, it is safe to do these activities or work after taking Minirin Melt 0.1 Tablet as it does not make you drowsy.
Is it safe?
Minirin Melt 0.1 Tablet should be used only after doctor's advice.
Is it able to treat mental disorders?
No, Minirin Melt 0.1 Tablet cannot treat any kind of mental disorder.
Interaction between Food and Minirin Melt 0.1 Tablet
There is no information on the effects of taking Minirin Melt 0.1 Tablet with food, because this topic has not been scientifically researched yet.
Interaction between Alcohol and Minirin Melt 0.1 Tablet
Information about the interaction of Minirin Melt 0.1 Tablet and alcohol is not currently available because this topic has not been researched yet.
This medicine data has been created by -
B.Pharma, Pharmacy
7 Years of Experience
References
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 413-415
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 596-597
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Ddavp® (desmopressin acetate)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Noctiva™ (desmopressin acetate)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Nocdurna® (desmopressin acetate)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Stimate® (desmopressin acetate)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 413-415
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 596-597
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Ddavp® (desmopressin acetate)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Noctiva™ (desmopressin acetate)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Nocdurna® (desmopressin acetate)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Stimate® (desmopressin acetate)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 413-415
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 596-597
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Ddavp® (desmopressin acetate)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Noctiva™ (desmopressin acetate)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Nocdurna® (desmopressin acetate)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Stimate® (desmopressin acetate)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 413-415
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 596-597
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Ddavp® (desmopressin acetate)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Noctiva™ (desmopressin acetate)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Nocdurna® (desmopressin acetate)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Stimate® (desmopressin acetate)
